NACDS Announces 2013-2014 Officers, Welcomes New Board, Executive Committee Members during Annual Meeting

Published Online: Monday, April 22, 2013

April 22, 2013 (Palm Beach, Fla.) – During the National Association of Chain Drug Stores (NACDS) Annual Meeting today, the Association elected the new officers, two new Executive Committee members and four new Board of Directors members for the coming year.

Robert J. Narveson, president and chief executive officer of Thrifty White Pharmacy, was elected as the new NACDS chairman of the Board of Directors, succeeding Gregory D. Wasson, president and chief executive officer of Walgreen Co.

In addition, John Standley, chairman, president and chief executive officer of Rite Aid Corporation was elected vice chairman, and Juan M. Ortiz, chief executive officer, Navarro Discount Pharmacies, was elected treasurer.

“We are pleased to welcome Bob Narveson as NACDS chairman of the Board of Directors,” said NACDS President and CEO Steven C. Anderson, IOM, CAE.  “Serving as a Board officer and chairman of the NACDS Political Action Committee, Bob has displayed an incredible commitment to community pharmacy and NACDS.  We look forward to working with him in his new role as chairman of the Board in the coming year.”

In addition to the election of the new officers for one-year terms, the NACDS Board elected Dr. John Agwunobi, senior vice president and president of health and wellness of Wal-Mart Stores, Inc., and Juan Ortiz as new Executive Committee members.

Four new Board of Directors members were also elected: Randy Edeker, chairman and chief executive officer of Hy-Vee, Inc.; Dijuana Lewis, senior vice president of health care solutions for the Health and Wellness Division of Wal-Mart Stores, Inc.; Ken Martindale, chief operating officer of Rite Aid Corporation; and Martin Otto, chief merchant and chief financial officer of H-E-B.

These four new Board members will join the other 22 members of the NACDS Board of Directors to develop NACDS’ policies and priorities.

Latest Articles
Skipping a flu shot may put patients at greater risk for flu-related pneumonia.
This weekly video program highlights the latest in pharmacy news, product news, and more.
Mylan has launched a generic version of Teva Pharmaceuticals’ Adderall in 5 mg, 7.5 mg, 10 mg, 12.5 mg, 20 mg, and 30 mg doses.
The FDA has approved Boehringer Ingelheim’s oral direct thrombin inhibitor dabigatran etexilate mesylate (Pradaxa) for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who have had hip replacement surgery.
Latest Issues